Linked Life Data

9336357

Source:http://linkedlifedata.com/resource/pubmed/id/9336357

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1997-10-30
pubmed:abstractText
Lonidamine (LND) is an energolytic derivative of indazol-carboxylic acid that has been shown to enhance cisplatin (CDDP) activity in both sensitive (A2780) and resistant (A2780/Cp8) ovarian cancer cell lines. The aim of this study was to confirm the potentiating or reverting activity of LND on CDDP activity obtained in experimental models in a phase II study of advanced ovarian cancer patients previously treated with platinum-based regimens.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3208-13
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
pubmed:affiliation
Medical Oncology Division, Oncology Institute, Bari, Italy. vlor@mail5.clio.it
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase II